Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Orexigen’s Obesity Drug Empatic Meets Study Goal

By Pharmaceutical Processing | September 30, 2009

SAN DIEGO (AP) — Orexigen Therapeutics Inc. said Wednesday its potential obesity treatment Empatic met key goals in a midstage study and the company plans to move the drug candidate into late-stage development. Orexigen said it plans to meet with the Food and Drug Administration to discuss plans for a Phase III clinical trial. The drug is a combination of the antidepressant Wellbutrin and the seizure medication zonisamide. The study involved 729 people either taking Empatic or placebo. The company said 60.4 percent of patients given Empatic lost more than 5 percent of their body weight in the 24-week study, compared with 14.7 percent of patients taking placebo. Orexigen also has another obesity drug Contrave in late-stage development and plans to seek FDA approval in 2010. Contrave combines bupropion, a drug used to treat depression and smoking habits, with naltrexone, which is to used to fight alcoholism and opiate addiction. Orexigen could face competition as two other California-based companies, Arena Pharmaceuticals Inc. and Vivus Inc., seek to bring their own late-stage obesity drugs to market. Shares of Orexigen rose as much as 8.4 percent in premarket trading on Wednesday. Its shares recently changed hands at $9.93, up 10 cents. Meanwhile, shares of Arena gained 8 cents, or less than 1 percent, to $4.56, while Vivus advanced 87 cents, or 8.5 percent, to $11.07.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards